Pledge Therapeutics

Our team had an incredible week at NVIDIA's #GTC25 conference in San Jose, surrounded by some of the brightest minds pushing the frontiers of AI. From deep conversations on generative models and protein design, to hearing Jensen Huang and other innovators speak live about the future of accelerated computing—it’s clear we’re entering a new era of possibility. As a drug design and discovery company firmly rooted in experimental science, we could not be more excited about the future of biotech and medicine as we begin to train powerful AI models. We’ve been quietly working on revolutionary models built on one of the largest, curated, proprietary structural data sets ever assembled, and the preliminary results are astounding. The implications are vast. We recently launched Pledge-AI (https://pledge-tx.ai/) to realize and push the limits of what is possible when you merge deep human expertise with deep machine learning. We’re building at the edge of that convergence where: ·????????AI meets structure-based drug design exposing new drug-targeting opportunities ·????????GPU-powered proprietary models enable access to new chemical matter ·????????Hitting protein targets and interfaces that were once considered undruggable Big thanks to Drs. Asanga Bandara and Nick Hamilton for representing Pledge at the GTC 2025 —and to the NVIDIA team for making this such an inspiring experience. A shout out to the entire Pledge Therapeutics discovery team embedded within our AI group for all their innovative work. We're excited for what’s ahead in terms of collaborations and growth. #GTC #NVIDIA #AI #DrugDiscovery #PledgeTherapeutics #GPUpowered #AcceleratedComputing #Biotech #AIforDrugDiscovery #LifeSciences #StructuralBiology

Today, we announced the close of an oversubscribed $5.2M financing round, bringing Orthogon Therapeutics' total funding to over $25M.?Backed by a diversified investor base and a pipeline of drugs with unique mechanisms of action, Orthogon Therapeutics is addressing this area of urgent unmet medical need. With this renewed support, we are advancing our mission to develop the world’s first oral antiviral treatments for BK virus. Congratulations to our incredible team for their focus, and determination to transform treatment possibilities for BK virus infections! Orthogon Therapeutics, LLC is an independent, privately held R&D company affiliated with the Pledge Therapeutics discovery platform. More info at?www.pledge-tx.com.

Join Our Team! We’re looking for a Principal Scientist to lead protein and antibody engineering in our Rapid Response Group (RRG) within the Discovery Division. ?? The RRG is a hands-on, mission-driven team focused on high-impact projects, delivering tools, techniques, and data that drive our therapeutic programs forward. ?? If you're passionate about advancing science in a dynamic, collaborative environment, this could be the perfect opportunity! Apply today and be part of our transformative team Pledge Therapeutics! #Biotech #LifeSciences #Hiring #JobOpportunity #STEMCareers #JoinOurTeam

So far, it’s been a tremendous year at Pledge Therapeutics! We have expanded both our US and EU teams in the last 6 months. We're excited to welcome: US team (Canton, MA): Nagraj Mani, Senior Director, Virology Erin Deans, Scientist, Virology Consuelo Beatriz Correa Sierra, Senior Research Associate, Virology Rebecca Lashin (Riding), Senior Scientist, Immuno-Oncology Xue Yao, Scientist, Immuno-Oncology Krishna Kandala, Senior Associate, Business Development, Strategy & Operations Nick Hamilton, Postdoctoral Associate, Computational Chemist EU team (Leuven, BE): Senne Sienaert, Research Associate, Structural Biology As we grow our R&D, Computational Chemistry, and Business Development teams, we've opened some key positions to support our efforts at this exciting time in our growth journey. Please reach out to Maria Martin to inquire about these new positions or to join our talent network for future opportunities! #Biotech, #Startup # #Resarch #nowhiring #joinourteam www.pledge-tx.com

We are proud to see?Louise Sykora?graduate magna cum laude from KU Leuven with a Master’s in Biophysics, Biochemistry, and Biotechnology: Congratulations! It's thrilling to see how the passion for science and for pushing the boundaries of discovery are contagious! Keep up the amazing work—you're now officially part of our alumni crew; drop by anytime; always welcome. Congrats again on this fantastic milestone! Pledge Therapeutics?#teamwork #STEMGraduation #ProudAlumni

Pledge Therapeutics?and our CEO Dr.?Ali Munawar?are immersed in the Immuno-Oncology Summit Europe 2024 in London. With our groundbreaking advancements in our Immuno-Oncology pipeline, we look forward to lively breakout discussions, networking opportunities, and connecting with global leaders in the Immuno-Oncology space. #ImmunoOncology?#IOSummitUK?#DrugDiscovery?#Biopharma Our Immuno-Oncology programs reside under?Conformation-X Therapeutics?a company affiliated with?Pledge Therapeutics. https://lnkd.in/dgE7-xS

We are thrilled to announce that Conformation-X Therapeutics, affiliated with?Pledge Therapeutics, has emerged from stealth mode, securing an additional $3.65 million in funding. This brings our total raised to over $13.5 million since inception. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts. Read more:?https://lnkd.in/erAF-B9c Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.